Integrating human genomics and proteomics can help elucidate disease mechanisms,
identify clinical biomarkers and discover drug targets,,–. Because previous proteogenomic …

Although human genetics has substantial potential to illuminate novel disease pathways
and facilitate drug development, identifying causal variants and deciphering their …

Aortic disease, including dissection, aneurysm, and rupture, carries significant morbidity and
mortality and is a notable cause of sudden cardiac death. Much of our knowledge regarding …

Background The large extracellular matrix protein SVEP1 mediates cell adhesion via
integrin α9β1. Recent studies have identified an association between a missense variant in …

Coronary artery disease (CAD) remains a leading cause of disease burden globally, and
there is a persistent need for new therapeutic targets. Instrumental variable (IV) and genetic …

CD44 is associated with a high risk of metastasis, recurrence, and drug resistance in various
cancers. Here we report that platelet endothelial aggregation receptor 1 (PEAR1) is a CD44 …

Background Prognostic markers and biological pathways linked to detrimental clinical
outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely …

Background Clustering of the receptors glycoprotein receptor VI (GPVI), C-type lectin-like
receptor 2 (CLEC-2), low-affinity immunoglobulin γ Fc region receptor II-a (FcγRIIA), and …

Genetic studies of platelet reactivity (PR) phenotypes may identify novel antiplatelet drug
targets. However, such studies have been limited by small sample sizes (n< 5000) because …

BACKGROUND: Endothelial dysfunction and inflammation have been implicated in the
pathophysiology of cerebral small vessel disease (SVD). However, whether they are causal …